Skip to content
Screener

Alkermes ALKS Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$452.4M+182%
AbbVie logo
AbbVieABBV
$4.16B+1,293%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$17.83M-23.4%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$20M-138%
LBR
LB Pharmaceuticals IncLBRX
$70.51M+2,340%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Alkermes’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206534
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Employee taxes paid related to net share settlement of equity awards(23,442)(28,781)
Payment for the repurchase of ordinary shares(27,696)
Cash flows provided by financing activities1,474,519747
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(768,225)108,660
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period1,119,776291,146
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period$351,551$399,806
SUPPLEMENTAL CASH FLOW DISCLOSURE:
Cash paid for taxes$1,850$458

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's net change in cash?
Alkermes (ALKS) reported net change in cash of -$768.23M in Q1 2026.
How has Alkermes's net change in cash changed year-over-year?
Alkermes's net change in cash decreased by 807.0% year-over-year, from $108.66M to -$768.23M.
What is the long-term trend for Alkermes's net change in cash?
Over 2 years (2021 to 2025), Alkermes's net change in cash has grown at a 258.2% compound annual growth rate (CAGR), from $64.58M to $828.63M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Alkermes's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude